AstraZeneca Pharma India reported mixed financial results for Q1 FY27, with net profit declining 32.06% to ₹37.93 crore compared to ₹55.83 crore in the corresponding quarter last year. However, the pharmaceutical company demonstrated strong revenue growth, with revenue from operations increasing 29.73% to ₹682.79 crore from ₹526.31 crore year-on-year. According to the latest regulatory filing, the company's operational efficiency faced pressure as total expenses rose significantly to ₹641.03 crore from ₹462.49 crore in the previous year, contributing to the profit decline despite robust top-line performance. The operating profit margin (OPM) compressed to 7.17% from 15.41% in the previous year, indicating increased cost pressures across operations.
The company's core therapy areas showed robust growth across multiple segments during the quarter. As reported by Business Standard, the Oncology segment business grew 26% YoY to ₹464.9 crore, while the Biopharmaceuticals segment (CVRM, R&I and V&I) rose 36% YoY to ₹161.9 crore. The Rare Diseases segment business jumped 35x to ₹14.4 crore, indicating strong performance in specialized therapeutic areas. According to the company's release, the performance was driven by continued momentum across its core therapy areas including Oncology, Biopharmaceuticals, and Rare Disease segments.
During the quarter, AstraZeneca Pharma India strengthened its portfolio through key regulatory approvals and expanded scientific engagement through targeted capability-building initiatives. According to the company's statement, these efforts supported earlier diagnosis and broader access to treatments. The company advanced strategic partnerships that align with its focus on therapeutic areas where it has demonstrated strong market performance. Country President & Managing Director Praveen Rao Akkinepally emphasized that "The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India."
Following the earnings announcement, AstraZeneca Pharma shares were trading 1.18% lower at ₹8,091.80 on the BSE at 2:30 PM. As reported by NDTV Profit, the market reaction reflected investor concerns over the significant decline in profitability despite strong revenue growth, with the stock price moving against the positive revenue performance trend. The mixed investor sentiment reflects the market's focus on profitability metrics over revenue growth in the pharmaceutical sector.
